Singapore’s Diagnostics Development Hub said today it is partnering with The Feinstein Institute for Medical Research and i360medical to develop medical and diagnostic devices and tech.
The partnered groups will focus on technologies for surgical procedures, intraoperative diagnostics and diabetic management, according to a press release from The Feinstein Institute.
“As the aging population continues to grow, and with the rise of chronic diseases, medical diagnostics becomes increasingly critical within healthcare for early detection, prevention and treatment of diseases. The DxD Hub’s collaboration with the Feinstein Institute and i360 will catalyze the development of leading edge medical technologies and devices, and bring them quickly to global markets. This enables A*STAR to achieve value creation, value delivery and value capture from our R&D,” DxD Hub CEO Dr. Sidney Yee said in a press release.
The partnered companies said they plan to identify and evaluate pipeline projects as they look to develop projects with a high-potential for clinical and commercial impact. The agreement will give The Feinstein Institute access to DxD Hub’s Asian and i360’s European clinical networks.
“I am delighted that the DxD Hub, i360medical and the Feinstein Institute have concluded this agreement to collaborate in identifying, developing and advancing the adoption of new medical technologies that improve healthcare and patient outcomes around the world,” Feinstein Institute technology transfer arm veep Kirk Manogue said in prepared remarks.
The partnered companies said they hope to focus on and accelerate projects that address Asian and global needs, specifically.
“This is an important partnership because it not only provides for collaborative research and development of new solutions for unmet clinical needs, but it also offers significant reach to bring affordable solutions to patients worldwide — most particularly in the US, Asian and EU markets. Collectively, our organizations and respective scientific and clinical thought leaders will look to combine expertise and produce new and enduring surgical and diagnostic technologies. It’s exciting to join forces to identify and develop a global lifecycle plan for breakthrough technologies in the healthcare of tomorrow,” i360medical CEO Derek Young said in a prepared statement.